

BRAIN TUMOUR GROUP

Chair: Michael Weller, Zurich

Secretary: Jaap Reijneveld, Amsterdam

<http://www.eortc.org/research-groups>

GENERAL ASSEMBLY
October 10, 2018 [12:00 – 16:00]
EANO Conference Center Stockholm
Room C1-C3

Agenda

12.00 h	Welcome & Activity Report	M. Weller
12.15 h	Report from EORTC HQ	M. Vanlancker
12.30 h	Update from BTG Committees	
5	Translational research & pathology	P. French
5	Quality assurance	E. Razis
5	Quality of life	L. Dirven
5	Imaging	M. Smits
5	Meningioma	M. Preusser
5	CNS metastases	E. Le Rhun
13.00 h	Completed clinical trials and projects – research & publication activities	
5	22033-26022: Phase III Intergroup trial comparing temozolomide alone versus radiotherapy alone in high risk low-grade glioma patients.	B. Baumert & M. Hegi
5	26042-22042: Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: a phase-II and observation study.	D. Weber
10	26053-22054: Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON intergroup trial.	M. van den Bent
5	26091: Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial.	M. van den Bent
10	26101: Phase II trial exploring the sequence of bevacizumab and lomustine in	W. Wick

	patients with first recurrence of a glioblastoma & phase II and phase III	
10	1410: ABT 414 alone or ABT 414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group	M. van den Bent
10	1320: Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group	M. Preusser
14.00 h	Ongoing clinical studies	
10	1308: An international randomized phase III study of observation vs. immediate adjuvant radiotherapy for WHO grade II newly diagnosed and recurrent meningioma patients after total surgical resection (ROAM)	M. Preusser
10	1419: BTFC Longterm survival in glioblastoma	C. Hertler
10	1608: Study of TG02 in elderly newly diagnosed or adult relapsed patients with anaplastic astrocytoma or glioblastoma: a phase Ib study, STEAM	E. Le Rhun
10	1709: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma	P. Roth
15.00 h	Research projects	
	RP 1230 NOA-08 Nordic Cooperation (plus 26062)	T. Gorlia
	RP 1515 CODAGLIO QOL	J. Reijneveld
	RP 1542 Primary and recurrent glioblastoma	P. French
	RP 1654 MGMT	M. Hegi
	RP 1661 Central pathology review	M. Kros
	RP 1662 CENTRIC/CORE imaging projects	M. Weller
	RP 1663 Metformin	P. Hau
	RP 1664 Temporal muscle thickness	M. Preusser
	RP 1665 Potassium channel antagonists	F. Lefranc
	RP 1719 Myelosuppression	M. Weller
	RP 1721 QOL / cognition in long-term oligo patients	M. Klein
	RP 1759 AYA/TYA project	L. Dirix
	RP 1803 Act IV transfer tissue bank	M. Weller
	RP 1808 Levetiracetam and toxicity	K. Seystahl
15.20 h	Planned clinical trials	
10	26081-22086: Phase III intergroup study of temozolomide alone versus radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy with adjuvant PCV chemotherapy in patients with 1p/19q co-deleted anaplastic glioma or low grade glioma (CODEL)	W. Wick
10	1634: Standard therapy vs. personalized intensity-modulated therapy for newly diagnosed medulloblastoma in adults: an international phase 0, phase Ib and randomized phase II study (PersoMed-I)	P. Hau
10	1635: IDH mutated 1p/19q intact lower grade glioma following resection: wait or treat? The I-WOT study	M. van den Bent
10	1807: Randomized phase II trial of early radiosurgery versus delayed radiosurgery or other salvage treatment (EVER) with checkpoint inhibition (EVER-IO) for the treatment of patients with brain metastases from non-small cell lung cancer (NSCLC)	E. Le Rhun
15.40 h	Current issues and new initiatives	

16.00 h	Adjourn	M. Weller
	Next General Meeting: March 15, 2019, 14.00-18.00 h EGAM, Brussels, Belgium	